{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:20:33Z","timestamp":1768879233171,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.urolonc.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T07:41:41Z","timestamp":1666424501000},"page":"49.e1-49.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["What is the most effective way to ensure that patients successfully undergo germline testing for prostate cancer?"],"prefix":"10.1016","volume":"41","author":[{"given":"David","family":"Ahlborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilene","family":"Staff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.09.002_bib0001","unstructured":"National Cancer Institute: Genetics of prostate cancer (PDQ)-Health professional version. Available at: https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-genetics-pdq; 2022 [Accessed 4 April 2022]."},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.002_bib0002","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.002_bib0003","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2022.09.002_bib0004","first-page":"2017","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.002_bib0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.002_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.urolonc.2022.09.002_bib0007","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/hmg\/11.21.2591","article-title":"BRCA1 interacts directly with the Fanconi anemia protein FANCA","volume":"1","author":"Folias","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.urolonc.2022.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.002_bib0009","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicenter, open-label, randomized, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.urolonc.2022.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.002_bib0011","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.09.002_bib0012","first-page":"891","article-title":"Olaparib for metastatic castration-resistant prostate cancer. reply","volume":"383","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2022.09.002_bib0013","unstructured":"Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Available at:https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer; 2020 [Accessed 4\/7\/21]."},{"key":"10.1016\/j.urolonc.2022.09.002_bib0014","doi-asserted-by":"crossref","first-page":"v327","DOI":"10.1093\/annonc\/mdz248.003","article-title":"846PD - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses","volume":"30","author":"Abida","year":"2019","journal-title":"Ann. Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.002_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/onco.13585","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer","volume":"26","author":"Anscher","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.urolonc.2022.09.002_bib0016","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.09.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.676","volume":"36","author":"Ryan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.002_bib0018","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.euo.2020.07.005","article-title":"When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials","volume":"3","author":"Antonarakis","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.09.002_bib0019","unstructured":"The Genetic Information Nondiscrimination Act of 2008. Available at:https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-110publ233\/pdf\/PLAW-110publ233.pdf; 2008 [Accessed 2 April 2022]."},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.002_bib0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer version 2.2019 NCCN clinical practice guidelines in oncology","volume":"17","author":"James","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.002_bib0021","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"Guideline development group AeCoMGaGPPaGCaNSoGCPGC. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.002_bib0022","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1046\/j.1523-5394.2000.82006.x","article-title":"Genetic testing for prostate cancer. Willingness and predictors of interest","volume":"8","author":"Diefenbach","year":"2000","journal-title":"Cancer Pract"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.002_bib0023","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/GIM.0b013e31819b2425","article-title":"Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives","volume":"11","author":"Harris","year":"2009","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.002_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00002820-200202000-00007","article-title":"Interest in genetic prostate cancer susceptibility testing among African American men","volume":"25","author":"Weinrich","year":"2002","journal-title":"Cancer Nurs"},{"issue":"17","key":"10.1016\/j.urolonc.2022.09.002_bib0025","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.18.02181","article-title":"Germline testing for men with prostate cancer: navigating an expanding new world of genetic evaluation for precision therapy and precision management","volume":"37","author":"Giri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.002_bib0026","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1200\/OP.20.00399","article-title":"Evaluation of a mainstream model of genetic testing for men with prostate cancer","volume":"17","author":"Scheinberg","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.002_bib0027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clgc.2019.04.013","article-title":"Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium","volume":"17","author":"Channing","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.09.002_bib0028","article-title":"Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation","volume":"25","author":"Loeb","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.002_bib0029","doi-asserted-by":"crossref","first-page":"e33968","DOI":"10.1371\/journal.pone.0033968","article-title":"Genotyping performance between saliva and blood-derived genomic DNAs on the DMET array: a comparison","volume":"7","author":"Hu","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.002_bib0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392200309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392200309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:26:11Z","timestamp":1761042371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392200309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S107814392200309X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the most effective way to ensure that patients successfully undergo germline testing for prostate cancer?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}